Exxel Pharma, Inc. | WebDisclosure

Basculer en Français

8396	Companies
122097	Keywords
60577	Articles
65553	Press releases

Home
Companies
Exxel Pharma, Inc.

BRIEF

published on 05/01/2024 at 16:05, 7 months 20 days ago

Exxel Pharma to Showcase in Virtual Investor Lunch Break

Exxel Pharma EX937 Virtual Investor Event Chronic Cough Treatment Pharmaceutical Development
BRIEF

published on 05/01/2024 at 16:05, 7 months 20 days ago

Exxel Pharma sera présent lors d'une pause déjeuner virtuelle pour les investisseurs

Exxel Pharma EX937 Événement Virtuel Pour Les Investisseurs Traitement De La Toux Chronique Développement Pharmaceutique
PRESS RELEASE

published on 05/01/2024 at 16:00, 7 months 20 days ago

Exxel Pharma to Participate in the Virtual Investor Lunch Break: The Exxel Opportunity
Soren Mogelsvang, PhD, CEO of Exxel Pharma, to present at Virtual Investor Lunch Break event discussing Exxel opportunity on May 8th. EX937 development updates

Exxel Pharma EX937 Virtual Investor Lunch Break Chronic Cough Treatment Soren Mogelsvang
PRESS RELEASE

published on 01/25/2024 at 16:00, 10 months 27 days ago

Exxel Pharma Provides Business Overview and Upcoming Milestones
Exxel Pharma provided a business overview of its lead program, EX937, an innovative small molecule for treating refractory chronic cough, a condition currently with no FDA-approved therapies. The program demonstrates a differentiated approach with preclinical efficacy and safety, aiming for potential value-driving milestones in 2024 and addressing a large underserved market. The company expects EX937 to have a significant impact on improving the quality of life for adults suffering from chronic cough, with potential broad clinical applications and commercial opportunities.

Exxel Pharma EX937 Refractory Chronic Cough FAA Enzyme Neuronal Hypersensitivity
PRESS RELEASE

published on 10/11/2023 at 16:00, 1 year 2 months ago

Exxel Pharma to Participate in the Virtual Investor Ask the CEO Conference

Accesswire

Published on 12/21/2024 at 01:30, 17 hours 56 minutes ago

Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 17 hours 56 minutes ago

iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 19 hours 21 minutes ago

Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/21/2024 at 00:00, 19 hours 26 minutes ago

Amarc Announces Loan Extension
Published on 12/20/2024 at 23:30, 19 hours 56 minutes ago

Boron One Announces Extension to Early Warrant Exercise Incentive Program

View all ACCESSWIRE

EQS Group

Published on 12/21/2024 at 00:51, 18 hours 35 minutes ago

Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 18 hours 41 minutes ago

EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 19:10, 1 day ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/20/2024 at 18:56, 1 day ago

CPI PROPERTY GROUP – Progress on Key Initiatives
Published on 12/20/2024 at 18:00, 1 day 1 hour ago

ARYZTA AG Announces New Board Technology Committee

Les Echos

Published on 12/21/2024 at 12:17, 7 hours 8 minutes ago

AXA annonce la signature d’un accord relatif à la vente d'AXA Investment Managers à BNP Paribas
Published on 12/21/2024 at 12:17, 7 hours 8 minutes ago

AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 1 day 1 hour ago

Kapitaalverhoging door uitoefening van inschrijvingsrechten
Published on 12/20/2024 at 18:00, 1 day 1 hour ago

Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 1 day 1 hour ago

Déclaration des transactions sur actions propres réalisées du 16/12/2024 au 20/12/2024

View all LES ECHOS COMFI WIRE